Hutchmed Regulatory News (HCM)

19 May 2006 07:01

Hutchison China Meditech Limited19 May 2006 This announcement is not for publication, release or distribution in whole or inpart in Australia, Canada, Japan, the Republic of Ireland, the Republic of SouthAfrica, the Cayman Islands or the United States. For Immediate Release 19th May 2006 Hutchison China MediTech Limited ("Chi-Med") First day of dealings on AIM Chi-Med announces that admission to trading on AIM will become effective, anddealings in the ordinary shares of the Company will start, at 8.00am today, 19thMay 2006, under the ticker symbol "HCM". The ISIN number will be KYG4672N1016.Dealings will be conducted in CREST through Depository Interests eachrepresenting an interest in one ordinary share. Chi-Med is the holding company of a pharmaceutical and healthcare group basedprimarily in China and focused on researching, developing, manufacturing, andselling pharmaceuticals, health supplements and other consumer health andpersonal care products derived from Traditional Chinese Medicine ("TCM") andbotanical ingredients. Chi-Med's overall aim is to draw on the untapped wealthof knowledge and history of usage in the TCM industry to develop pharmaceuticaland consumer products for the global market. On 10th May 2006, Chi-Med announced that it will have raised gross proceeds ofapproximately £40 million through a placing with institutional and otherqualified investors and via a Hong Kong Preferential Offering to qualifyingshareholders of Hutchison Whampoa Limited of a total of 14,545,454 new shares ata price of 275 pence per ordinary share (the "Placing Price"). Based on thatPlacing Price, the market capitalisation of Chi-Med on admission will beapproximately £141 million. Lazard & Co., Limited is Nominated Advisor to Chi-Med and Panmure Gordon areBrokers to the Placing. ContactsLazard & Co., LimitedPaul GismondiPeter CoupeTel: +44 (0) 20 7187 2000 Panmure GordonRichard GrayGilbert EllacombeTel: +44 (0) 20 7459 3600 Citigate Dewe Rogerson Anthony Carlisle (Mobile: + 44 (0) 7973 611 888)Chris GardnerSarah GestetnerTel: +44 (0) 20 7638 9571 Lazard & Co., Limited ("Lazard") of 50 Stratton Street, London W1J 8LL, isacting exclusively for Chi-Med and no-one else in connection with Admission andthe Placing and will not be responsible to anyone other than Chi-Med forproviding the protections afforded to the clients of Lazard, nor for providingadvice in relation to Admission or the Placing, the contents of thisannouncement or any transaction, arrangement or other matter referred to herein. Panmure Gordon (Broking) Limited ("Panmure Gordon"), of 155 Moorgate, LondonEC2M 6XB, is acting exclusively for Chi-Med and no-one else in connection withthe Placing and will not be responsible to anyone other than Chi-Med forproviding the protections afforded to the clients of Panmure Gordon, nor forproviding advice in relation to the Placing, the contents of this announcementor any transaction, arrangement or other matter referred to herein. This announcement does not constitute an offer of, or the solicitation of anoffer to buy or subscribe for, Ordinary Shares to any person in any jurisdictionto whom or in which such offer or solicitation is unlawful and, in particular,is not for release, publication or distribution in or into Australia, Canada,Japan, The Republic or Ireland, The Republic of South Africa, the Cayman Islandsor the United States. The offer and sale of the ordinary shares has not been and will not beregistered under the US Securities Act of 1933, as amended (the "SecuritiesAct") or under the applicable securities laws of Australia, Canada, Japan, TheRepublic or Ireland, The Republic of South Africa or the Cayman Islands. Subjectto certain exceptions, the ordinary shares may not be offered or sold inAustralia, Canada, Japan, the Republic of Ireland, the Republic of South Africa,the Cayman Islands or the United States. This information is provided by RNS The company news service from the London Stock Exchange